Polysulfated Glycosaminoglycan for Macaws: Uses, Dosing & Side Effects

This information is for educational purposes only. Never give your pet any medication without your veterinarian's guidance. Dosing, frequency, and safety depend on your pet's specific health profile.

Polysulfated glycosaminoglycan, often shortened to PSGAG, is an injectable joint medication your vet may use for some macaws with arthritis or other noninfectious joint disease. In dogs, it is best known under the brand name Adequan. In birds, including macaws, its use is extra-label, which means avian vets use it based on published avian references and clinical experience rather than a bird-specific FDA label.

PSGAG is considered a chondroprotective medication. That means it is intended to support joint cartilage and joint fluid rather than acting like a classic pain reliever. In practical terms, your vet may use it as one part of a broader arthritis plan that can also include weight management, perch changes, physical therapy, and pain-control medications.

For macaws, this medication is usually considered when stiffness, reduced climbing, reluctance to perch, or chronic joint wear are affecting comfort and mobility. It is not a home remedy and it is not appropriate for every sore bird. Your vet will first want to sort out whether the problem is more likely arthritis, trauma, infection, gout, or another condition, because those problems can look similar but need very different care.

In birds, PSGAG is most often discussed for osteoarthritis and degenerative joint disease. Merck Veterinary Manual lists it among drugs used for osteoarthritis in birds, which supports its role as an avian arthritis option when your vet feels the benefits outweigh the risks. In a macaw, that may mean chronic wear in the feet, hocks, hips, or other joints that makes movement slower or more painful.

Your vet may also consider it for traumatic arthritis or chronic joint inflammation after an old injury. Some birds seem to do best when PSGAG is paired with other supportive steps, such as padded or varied-diameter perches, easier cage access, lower climbing demands, and careful body-weight management.

It is not a good fit for every joint problem. PSGAG should not be used as a substitute for diagnosing infectious arthritis or articular gout, both of which can mimic arthritis in birds. If a macaw has a hot, swollen joint, sudden severe pain, fever, weakness, or signs of illness, your vet may recommend imaging, bloodwork, or joint sampling before choosing treatment.

For birds, Merck Veterinary Manual lists polysulfated glycosaminoglycan at 5 mg/kg by intramuscular injection once weekly for 4 weeks, then monthly. That is the commonly cited avian reference dose, but it should be treated as a starting framework, not a universal recipe. Macaws vary widely in size, muscle mass, hydration status, and underlying disease, so your vet may adjust the plan.

Because this is an injectable medication, dosing should be calculated by your vet from your bird's current gram weight and overall health picture. Injection site selection matters in birds, and so does technique. A macaw with liver disease, kidney disease, bruising, or a history of bleeding may need a different plan or a different medication entirely.

Do not try to convert dog instructions to a bird dose at home. Your vet may also change the schedule if your macaw is receiving other arthritis medications, has a fragile condition, or shows any bruising after treatment. Recheck visits are important, because the goal is not only to give the medication safely but also to confirm that it is actually improving comfort and function.

Bird-specific caution is important with this drug. Merck notes that PSGAG should be used with caution in birds because fatal coagulopathies from injection have occurred. In plain language, this means serious bleeding or clotting problems have been reported in avian patients. That does not mean every macaw will have trouble, but it does mean your vet will weigh risks carefully before using it.

More routine side effects reported for PSGAG in veterinary use include temporary injection-site pain, mild digestive upset such as vomiting or diarrhea in mammals, and abnormal bleeding. In a macaw, pet parents may notice bruising, weakness, unusual bleeding from an injection site, black or tarry droppings, increased sleepiness, or a sudden drop in activity after treatment.

See your vet immediately if your macaw seems pale, collapses, has labored breathing, develops marked swelling, bleeds more than expected, or becomes dramatically weaker after an injection. Also call promptly if the joint becomes hotter, more swollen, or more painful, because infection, worsening inflammation, or a different diagnosis may need to be ruled out.

The biggest interaction concern with PSGAG is its heparin-like effect on bleeding. VCA advises caution when it is used with anticoagulants such as heparin or warfarin and with antiplatelet drugs such as aspirin or clopidogrel, because the risk of abnormal bleeding may increase. While those exact drugs are not routine for most macaws, the same principle matters in birds receiving any medication or supplement that could affect clotting.

VCA also notes caution with glucocorticoids because steroids can mask signs of joint infection. That matters in birds, where infectious arthritis can be easy to miss early. If your macaw is already taking anti-inflammatory medication, pain medication, herbal products, or supplements, your vet should review the full list before starting PSGAG.

Be sure to tell your vet about any history of liver disease, kidney disease, bruising, recent surgery, or unexplained bleeding. Those details can change whether PSGAG is a reasonable option, whether monitoring is needed, or whether another arthritis plan would be safer for your bird.